1,2 CyA is presently used with steroids to prevent the rejection of transplanted kidneys,3 livers,4 and hearts
In order for CyA to undergo any significant enterohepatic recirculation, large amounts of CyA must be excreted in the bile
15 Rifampin, phenytoin, and phenobarbital, inducers of the hepatic P 450 enzyme system
As a result of cyclosporine-induced inhibition of the enterohepatic recirculation of mycophenolate, the mycophenolic acid area under the curve is
When native cyclosporine and metabolite concentrations are measured, second peaks in
Cyclosporine and AM1 were potent inhibitors of OATP1B1 and OATP1B3, IC 50 ranging from 0
It also has use in certain other autoimmune diseases, treatment of organ rejection in kidney, liver, and heart
Biliary excretion of CsA and its metabolites is the major route of drug elimination
Cyclosporine is approved for a variety of conditions
Cycling is often associated with multiple peaks and a longer apparent half-life in a plasma concentration-time profile
2 mg/kg/day for adults, 9
This latter mechanism compensates for the daily facal loss (about 0
If significant quantities of an active or toxic substance are present in bile, enterohepatic recirculation of those compounds might have a 1 Enterohepatic Circulation (EHC) - Definition
The first sign of hepatotoxicity was a reduction of bile flow amounting to 50% already at 50 mg/l CS
In nephrotic syndrome, manufacturer advises initial dose should not exceed 2
10 Several patients who developed neurotoxicity while on cyclosporine also reported that the
Purpose To apply physiologically-based pharmacokinetic (PBPK) modeling to investigate the consequences of reduction in activity of hepatic and intestinal uptake and efflux transporters by cyclosporine and its metabolite AM1
A recirculating isolated perfused rat liver model was used to investigate the hepatobiliary disposition of etoposide and the effects of cyclosporine A (CyA) on the pattern of drug disposition in All patients had normal liver tests before treatment and had at least six determinations during a 6- to 36-month course of therapy with cyclosporine A at a dose of 2-10 mg/kg/day
CBP decreased the MPA C 0 in Chinese HSCT patients even when MMF is used in combination with cyclosporine and rifaximin
647 and 0